Predictors of MTX monotherapy treatment success among patients with RA include low disease activity, normal body weight and ESR levels, and fewer tender joints.

The following is a summary of “High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis,” published in the October 2024 issue ...

A new study published in the Journal of the European Academy of Dermatology and Venereology found that methotrexate (MTX) has ...

will share ex vivo data demonstrating the efficacy of DC-9476 in cells from RA patients that have had an inadequate response to methotrexate (MTX-IR). RA affects approximately 1% of the population ...

Researchers have discovered that methotrexate (MTX) therapy may substantially diminish vaccine-induced CD4 T cell activation resulting in decreased antibody responses in rheumatoid arthritis (RA) ...

Low-risk patients with gestational trophoblastic disease (GTD) are initially treated with methotrexate (MTX)/folinic acid (FA) as this regimen is well tolerated and has no long-term sequelae.

Int J Clin Rheumatol. 2012;7(2):179-189. Together, the use of MTX in combination with other DMARDs still represents a valuable therapeutic option in patients who fail DMARD monotherapy or for whom ...

Background: DNA damage induced by chemotherapy has duality. It affects the efficacy of chemotherapy and constrains its application. An increasing number of studies have shown that traditional Chinese ...